Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Prepublished online as a Blood First Edition Paper on April 24, 2003; DOI 10.1182/blood-2003-01-0019.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2003-01-0019v1
102/4/1389    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Salih, H. R.
Right arrow Articles by Steinle, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Salih, H. R.
Right arrow Articles by Steinle, A.
Related Collections
Right arrow Immunobiology
Right arrow Neoplasia
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

Blood, 15 August 2003, Vol. 102, No. 4, pp. 1389-1396

IMMUNOBIOLOGY

Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia

Helmut Rainer Salih, Holger Antropius, Friederike Gieseke, Stefan Zoltan Lutz, Lothar Kanz, Hans-Georg Rammensee, and Alexander Steinle

From the Department of Internal Medicine II, University Hospital, Eberhard-Karls-University, Tübingen, Germany; and Department of Immunology, Eberhard-Karls-University, Tübingen, Germany

NKG2D ligands (NKG2DLs) mark malignant cells for recognition by natural killer (NK) cells and cytotoxic T lymphocytes via the activating immunoreceptor NKG2D. This led to the hypothesis that NKG2DLs play a critical role in tumor immune surveillance. The human NKG2DLs MICA and MICB are expressed on tumors of epithelial origin in vivo. For the other recently described set of human NKG2DLs, the UL16-binding proteins (ULBPs), expression in vivo is as yet undefined. In this study we investigated expression and function of NKG2DLs in leukemia using a panel of newly generated NKG2DL-specific monoclonal antibodies. We report that leukemia cells from patients variously express MIC and ULBP molecules on the cell surface with MICA most frequently detected. Patient leukemia cells expressing MICA were lysed by NK cells in an NKG2D-dependent fashion. Sera of patients, but not of healthy donors, contained elevated levels of soluble MICA (sMICA). We also detected increased sMICB levels in patient sera using a newly established MICB-specific enzyme-linked immunosorbent assay. Reduction of leukemia MIC surface expression by shedding may impair NKG2D-mediated immune surveillance of leukemias. In addition, determination of sMICA and sMICB levels may be implemented as a prognostic parameter in patients with hematopoietic malignancies.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
haematolHome page
U. Langenkamp, U. Siegler, S. Jorger, S. Diermayr, A. Gratwohl, C. P. Kalberer, and A. Wodnar-Filipowicz
Human acute myeloid leukemia CD34+CD38- stem cells are susceptible to allorecognition and lysis by single KIR-expressing natural killer cells
Haematologica, November 1, 2009; 94(11): 1590 - 1594.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
K. Kohga, T. Takehara, T. Tatsumi, T. Miyagi, H. Ishida, K. Ohkawa, T. Kanto, N. Hiramatsu, and N. Hayashi
Anticancer Chemotherapy Inhibits MHC Class I-Related Chain A Ectodomain Shedding by Downregulating ADAM10 Expression in Hepatocellular Carcinoma
Cancer Res., October 15, 2009; 69(20): 8050 - 8057.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
H.-G. Kopp, T. Placke, and H. R. Salih
Platelet-Derived Transforming Growth Factor-{beta} Down-Regulates NKG2D Thereby Inhibiting Natural Killer Cell Antitumor Reactivity
Cancer Res., October 1, 2009; 69(19): 7775 - 7783.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. Paschen, A. Sucker, B. Hill, I. Moll, M. Zapatka, X. D. Nguyen, G. C. Sim, I. Gutmann, J. Hassel, J. C. Becker, et al.
Differential Clinical Significance of Individual NKG2D Ligands in Melanoma: Soluble ULBP2 as an Indicator of Poor Prognosis Superior to S100B
Clin. Cancer Res., August 15, 2009; 15(16): 5208 - 5215.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. Hedlund, A.-C. Stenqvist, O. Nagaeva, L. Kjellberg, M. Wulff, V. Baranov, and L. Mincheva-Nilsson
Human Placenta Expresses and Secretes NKG2D Ligands via Exosomes that Down-Modulate the Cognate Receptor Expression: Evidence for Immunosuppressive Function
J. Immunol., July 1, 2009; 183(1): 340 - 351.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
P. Roda-Navarro and H. T. Reyburn
The Traffic of the NKG2D/Dap10 Receptor Complex during Natural Killer (NK) Cell Activation
J. Biol. Chem., June 12, 2009; 284(24): 16463 - 16472.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. Lundqvist, H. Yokoyama, A. Smith, M. Berg, and R. Childs
Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells
Blood, June 11, 2009; 113(24): 6120 - 6127.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. E. Butler, M. B. Moore, S. R. Presnell, H.-W. Chan, N. J. Chalupny, and C. T. Lutz
Proteasome Regulation of ULBP1 Transcription
J. Immunol., May 15, 2009; 182(10): 6600 - 6609.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
C. Cerboni, M. Ardolino, A. Santoni, and A. Zingoni
Detuning CD8+ T lymphocytes by down-regulation of the activating receptor NKG2D: role of NKG2D ligands released by activated T cells
Blood, March 26, 2009; 113(13): 2955 - 2964.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. Charni, J. I. Aguilo, J. Garaude, G. de Bettignies, C. Jacquet, R. A. Hipskind, D. Singer, A. Anel, and M. Villalba
ERK5 Knockdown Generates Mouse Leukemia Cells with Low MHC Class I Levels That Activate NK Cells and Block Tumorigenesis
J. Immunol., March 15, 2009; 182(6): 3398 - 3405.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
P. Boutet, S. Aguera-Gonzalez, S. Atkinson, C. J. Pennington, D. R. Edwards, G. Murphy, H. T. Reyburn, and M. Vales-Gomez
Cutting Edge: The Metalloproteinase ADAM17/TNF-{alpha}-Converting Enzyme Regulates Proteolytic Shedding of the MHC Class I-Related Chain B Protein
J. Immunol., January 1, 2009; 182(1): 49 - 53.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. Kloss, P. Decker, K. M. Baltz, T. Baessler, G. Jung, H.-G. Rammensee, A. Steinle, M. Krusch, and H. R. Salih
Interaction of Monocytes with NK Cells upon Toll-Like Receptor-Induced Expression of the NKG2D Ligand MICA
J. Immunol., November 15, 2008; 181(10): 6711 - 6719.
[Abstract] [Full Text] [PDF]


Home page
Protein Eng Des SelHome page
C. Germain, E. Campigna, I. Salhi, S. Morisseau, I. Navarro-Teulon, J.-P. Mach, A. Pelegrin, and B. Robert
Redirecting NK cells mediated tumor cell lysis by a new recombinant bifunctional protein
Protein Eng. Des. Sel., November 1, 2008; 21(11): 665 - 672.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
I. Waldhauer, D. Goehlsdorf, F. Gieseke, T. Weinschenk, M. Wittenbrink, A. Ludwig, S. Stevanovic, H.-G. Rammensee, and A. Steinle
Tumor-Associated MICA Is Shed by ADAM Proteases
Cancer Res., August 1, 2008; 68(15): 6368 - 6376.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
W. Cao, X. Xi, Z. Wang, L. Dong, Z. Hao, L. Cui, C. Ma, and W. He
Four novel ULBP splice variants are ligands for human NKG2D
Int. Immunol., August 1, 2008; 20(8): 981 - 991.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
N. Dulphy, P. Haas, M. Busson, S. Belhadj, R. Peffault de Latour, M. Robin, M. Carmagnat, P. Loiseau, R. Tamouza, C. Scieux, et al.
An Unusual CD56brightCD16low NK Cell Subset Dominates the Early Posttransplant Period following HLA-Matched Hematopoietic Stem Cell Transplantation
J. Immunol., August 1, 2008; 181(3): 2227 - 2237.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. A. Caligiuri
Human natural killer cells
Blood, August 1, 2008; 112(3): 461 - 469.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
A. Iannello, O. Debbeche, S. Samarani, and A. Ahmad
Antiviral NK cell responses in HIV infection: I. NK cell receptor genes as determinants of HIV resistance and progression to AIDS
J. Leukoc. Biol., July 1, 2008; 84(1): 1 - 26.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
A. Iannello, O. Debbeche, S. Samarani, and A. Ahmad
Antiviral NK cell responses in HIV infection: II. viral strategies for evasion and lessons for immunotherapy and vaccination
J. Leukoc. Biol., July 1, 2008; 84(1): 27 - 49.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
B. Le Maux Chansac, D. Misse, C. Richon, I. Vergnon, M. Kubin, J.-C. Soria, A. Moretta, S. Chouaib, and F. Mami-Chouaib
Potentiation of NK cell-mediated cytotoxicity in human lung adenocarcinoma: role of NKG2D-dependent pathway
Int. Immunol., July 1, 2008; 20(7): 801 - 810.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. Armeanu, M. Krusch, K. M. Baltz, T. S. Weiss, I. Smirnow, A. Steinle, U. M. Lauer, M. Bitzer, and H. R. Salih
Direct and Natural Killer Cell-Mediated Antitumor Effects of Low-Dose Bortezomib in Hepatocellular Carcinoma
Clin. Cancer Res., June 1, 2008; 14(11): 3520 - 3528.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Vales-Gomez, S. E. Chisholm, R. L. Cassady-Cain, P. Roda-Navarro, and H. T. Reyburn
Selective Induction of Expression of a Ligand for the NKG2D Receptor by Proteasome Inhibitors
Cancer Res., March 1, 2008; 68(5): 1546 - 1554.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. Diermayr, H. Himmelreich, B. Durovic, A. Mathys-Schneeberger, U. Siegler, U. Langenkamp, J. Hofsteenge, A. Gratwohl, A. Tichelli, M. Paluszewska, et al.
NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities
Blood, February 1, 2008; 111(3): 1428 - 1436.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
Y.-J. Kim, M.-K. Han, and H. E. Broxmeyer
4-1BB regulates NKG2D costimulation in human cord blood CD8+ T cells
Blood, February 1, 2008; 111(3): 1378 - 1386.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. I. Marusina, S. J. Burgess, I. Pathmanathan, F. Borrego, and J. E. Coligan
Regulation of Human DAP10 Gene Expression in NK and T Cells by Ap-1 Transcription Factors
J. Immunol., January 1, 2008; 180(1): 409 - 417.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. Maccalli, D. Nonaka, A. Piris, D. Pende, L. Rivoltini, C. Castelli, and G. Parmiani
NKG2D-Mediated Antitumor Activity by Tumor-Infiltrating Lymphocytes and Antigen-Specific T-Cell Clones Isolated from Melanoma Patients
Clin. Cancer Res., December 15, 2007; 13(24): 7459 - 7468.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
T. Zhang, A. Barber, and C. L. Sentman
Chimeric NKG2D Modified T Cells Inhibit Systemic T-Cell Lymphoma Growth in a Manner Involving Multiple Cytokines and Cytotoxic Pathways
Cancer Res., November 15, 2007; 67(22): 11029 - 11036.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. V. Girart, M. B. Fuertes, C. I. Domaica, L. E. Rossi, and N. W. Zwirner
Engagement of TLR3, TLR7, and NKG2D Regulate IFN-{gamma} Secretion but Not NKG2D-Mediated Cytotoxicity by Human NK Cells Stimulated with Suboptimal Doses of IL-12
J. Immunol., September 15, 2007; 179(6): 3472 - 3479.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
K. M. Baltz, M. Krusch, A. Bringmann, P. Brossart, F. Mayer, M. Kloss, T. Baessler, I. Kumbier, A. Peterfi, S. Kupka, et al.
Cancer immunoediting by GITR (glucocorticoid-induced TNF-related protein) ligand in humans: NK cell/tumor cell interactions
FASEB J, August 1, 2007; 21(10): 2442 - 2454.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
W. Cao, X. Xi, Z. Hao, W. Li, Y. Kong, L. Cui, C. Ma, D. Ba, and W. He
RAET1E2, a Soluble Isoform of the UL16-binding Protein RAET1E Produced by Tumor Cells, Inhibits NKG2D-mediated NK Cytotoxicity
J. Biol. Chem., June 29, 2007; 282(26): 18922 - 18928.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
P. Roda-Navarro and H. T. Reyburn
Intercellular protein transfer at the NK cell immune synapse: mechanisms and physiological significance
FASEB J, June 1, 2007; 21(8): 1636 - 1646.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
P. K. Epling-Burnette, F. Bai, J. S. Painter, D. E. Rollison, H. R. Salih, M. Krusch, J. Zou, E. Ku, B. Zhong, D. Boulware, et al.
Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors
Blood, June 1, 2007; 109(11): 4816 - 4824.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Barber, T. Zhang, L. R. DeMars, J. Conejo-Garcia, K. F. Roby, and C. L. Sentman
Chimeric NKG2D Receptor-Bearing T Cells as Immunotherapy for Ovarian Cancer
Cancer Res., May 15, 2007; 67(10): 5003 - 5008.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. Catellani, A. Poggi, A. Bruzzone, P. Dadati, J. L. Ravetti, M. Gobbi, and M. R. Zocchi
Expansion of V{delta}1 T lymphocytes producing IL-4 in low-grade non-Hodgkin lymphomas expressing UL-16-binding proteins
Blood, March 1, 2007; 109(5): 2078 - 2085.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
P. Saikali, J. P. Antel, J. Newcombe, Z. Chen, M. Freedman, M. Blain, R. Cayrol, A. Prat, J. A. Hall, and N. Arbour
NKG2D-Mediated Cytotoxicity toward Oligodendrocytes Suggests a Mechanism for Tissue Injury in Multiple Sclerosis
J. Neurosci., January 31, 2007; 27(5): 1220 - 1228.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
T. Osaki, H. Saito, T. Yoshikawa, S. Matsumoto, S. Tatebe, S. Tsujitani, and M. Ikeguchi
Decreased NKG2D Expression on CD8+ T Cell Is Involved in Immune Evasion in Patients with Gastric Cancer
Clin. Cancer Res., January 15, 2007; 13(2): 382 - 387.
[Abstract] [Full Text] [PDF]


Home page
J. Gen. Virol.Home page
C. Cerboni, F. Neri, N. Casartelli, A. Zingoni, D. Cosman, P. Rossi, A. Santoni, and M. Doria
Human immunodeficiency virus 1 Nef protein downmodulates the ligands of the activating receptor NKG2D and inhibits natural killer cell-mediated cytotoxicity
J. Gen. Virol., January 1, 2007; 88(1): 242 - 250.
[Abstract] [Full Text] [PDF]


Home page
ASH ANNUAL MEETING ABSTRACTSHome page
U. Mura, M. Pfeiffer, R. Handgretinger, and P. J. Lang
Expression of Activating Natural Killer Cell Receptor Ligands in Childhood Acute Lymphoblastic Leukemia.
Blood (ASH Annual Meeting Abstracts), November 16, 2006; 108(11): 4478 - 4478.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
V. Trichet, C. Benezech, C. Dousset, M.-C. Gesnel, M. Bonneville, and R. Breathnach
Complex Interplay of Activating and Inhibitory Signals Received by V{gamma}9V{delta}2 T Cells Revealed by Target Cell beta2-Microglobulin Knockdown
J. Immunol., November 1, 2006; 177(9): 6129 - 6136.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Lopez-Soto, A. Quinones-Lombrana, R. Lopez-Arbesu, C. Lopez-Larrea, and S. Gonzalez
Transcriptional Regulation of ULBP1, a Human Ligand of the NKG2D Receptor
J. Biol. Chem., October 13, 2006; 281(41): 30419 - 30430.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. Spreu, T. Stehle, and A. Steinle
Human Cytomegalovirus-Encoded UL16 Discriminates MIC Molecules by Their {alpha}2 Domains.
J. Immunol., September 1, 2006; 177(5): 3143 - 3149.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
G. Eisele, J. Wischhusen, M. Mittelbronn, R. Meyermann, I. Waldhauer, A. Steinle, M. Weller, and M. A. Friese
TGF-{beta} and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells
Brain, September 1, 2006; 129(9): 2416 - 2425.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
T. Zhang, A. Barber, and C. L. Sentman
Generation of Antitumor Responses by Genetic Modification of Primary Human T Cells with a Chimeric NKG2D Receptor
Cancer Res., June 1, 2006; 66(11): 5927 - 5933.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Gasser and D. H. Raulet
The DNA damage response arouses the immune system.
Cancer Res., April 15, 2006; 66(8): 3959 - 3962.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
N. Boissel, D. Rea, V. Tieng, N. Dulphy, M. Brun, J.-M. Cayuela, P. Rousselot, R. Tamouza, P. Le Bouteiller, F.-X. Mahon, et al.
BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia.
J. Immunol., April 15, 2006; 176(8): 5108 - 5116.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
L. Mincheva-Nilsson, O. Nagaeva, T. Chen, U. Stendahl, J. Antsiferova, I. Mogren, J. Hernestal, and V. Baranov
Placenta-Derived Soluble MHC Class I Chain-Related Molecules Down-Regulate NKG2D Receptor on Peripheral Blood Mononuclear Cells during Human Pregnancy: A Possible Novel Immune Escape Mechanism for Fetal Survival
J. Immunol., March 15, 2006; 176(6): 3585 - 3592.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
I. Waldhauer and A. Steinle
Proteolytic Release of Soluble UL16-Binding Protein 2 from Tumor Cells.
Cancer Res., March 1, 2006; 66(5): 2520 - 2526.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
E. P. von Strandmann, H. P. Hansen, K. S. Reiners, R. Schnell, P. Borchmann, S. Merkert, V. R. Simhadri, A. Draube, M. Reiser, I. Purr, et al.
A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo
Blood, March 1, 2006; 107(5): 1955 - 1962.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. J. Burgess, A. I. Marusina, I. Pathmanathan, F. Borrego, and J. E. Coligan
IL-21 Down-Regulates NKG2D/DAP10 Expression on Human NK and CD8+ T Cells
J. Immunol., February 1, 2006; 176(3): 1490 - 1497.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
N. Hanaoka, T. Kawaguchi, K. Horikawa, S. Nagakura, H. Mitsuya, and H. Nakakuma
Immunoselection by natural killer cells of PIGA mutant cells missing stress-inducible ULBP
Blood, February 1, 2006; 107(3): 1184 - 1191.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Skov, M. T. Pedersen, L. Andresen, P. Thor Straten, A. Woetmann, and N. Odum
Cancer Cells Become Susceptible to Natural Killer Cell Killing after Exposure to Histone Deacetylase Inhibitors Due to Glycogen Synthase Kinase-3-Dependent Expression of MHC Class I-Related Chain A and B
Cancer Res., December 1, 2005; 65(23): 11136 - 11145.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
G. Sconocchia, M. Lau, M. Provenzano, K. Rezvani, W. Wongsena, H. Fujiwara, N. Hensel, J. Melenhorst, J. Li, S. Ferrone, et al.
The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D-target-cell interactions
Blood, November 15, 2005; 106(10): 3666 - 3672.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. Germain, C. Larbouret, V. Cesson, A. Donda, W. Held, J.-P. Mach, A. Pelegrin, and B. Robert
MHC Class I-Related Chain A Conjugated to Antitumor Antibodies Can Sensitize Tumor Cells to Specific Lysis by Natural Killer Cells
Clin. Cancer Res., October 15, 2005; 11(20): 7516 - 7522.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
M. J. Smyth, J. Swann, E. Cretney, N. Zerafa, W. M. Yokoyama, and Y. Hayakawa
NKG2D function protects the host from tumor initiation
J. Exp. Med., September 6, 2005; 202(5): 583 - 588.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Girlanda, C. Fortis, D. Belloni, E. Ferrero, P. Ticozzi, C. Sciorati, M. Tresoldi, A. Vicari, T. Spies, V. Groh, et al.
MICA Expressed by Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance Plasma Cells Costimulates Pamidronate-Activated {gamma}{delta} Lymphocytes
Cancer Res., August 15, 2005; 65(16): 7502 - 7508.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
B. Rincon-Orozco, V. Kunzmann, P. Wrobel, D. Kabelitz, A. Steinle, and T. Herrmann
Activation of V{gamma}9V{delta}2 T Cells by NKG2D
J. Immunol., August 15, 2005; 175(4): 2144 - 2151.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Armeanu, M. Bitzer, U. M. Lauer, S. Venturelli, A. Pathil, M. Krusch, S. Kaiser, J. Jobst, I. Smirnow, A. Wagner, et al.
Natural Killer Cell-Mediated Lysis of Hepatoma Cells via Specific Induction of NKG2D Ligands by the Histone Deacetylase Inhibitor Sodium Valproate
Cancer Res., July 15, 2005; 65(14): 6321 - 6329.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Terme, C. Borg, F. Guilhot, C. Masurier, C. Flament, E. F. Wagner, S. Caillat-Zucman, A. Bernheim, A. G. Turhan, A. Caignard, et al.
BCR/ABL Promotes Dendritic Cell-Mediated Natural Killer Cell Activation
Cancer Res., July 15, 2005; 65(14): 6409 - 6417.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
K. Wiemann, H.-W. Mittrucker, U. Feger, S. A. Welte, W. M. Yokoyama, T. Spies, H.-G. Rammensee, and A. Steinle
Systemic NKG2D Down-Regulation Impairs NK and CD8 T Cell Responses In Vivo
J. Immunol., July 15, 2005; 175(2): 720 - 729.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
K. C. Hsu, C. A. Keever-Taylor, A. Wilton, C. Pinto, G. Heller, K. Arkun, R. J. O'Reilly, M. M. Horowitz, and B. Dupont
Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes
Blood, June 15, 2005; 105(12): 4878 - 4884.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
V. Groh, Y. Q. Li, D. Cioca, N. N. Hunder, W. Wang, S. R. Riddell, C. Yee, and T. Spies
From The Cover: Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells
PNAS, May 3, 2005; 102(18): 6461 - 6466.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
P. Nowbakht, M.-C. S. Ionescu, A. Rohner, C. P. Kalberer, E. Rossy, L. Mori, D. Cosman, G. De Libero, and A. Wodnar-Filipowicz
Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias
Blood, May 1, 2005; 105(9): 3615 - 3622.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
D. Pende, G. M. Spaggiari, S. Marcenaro, S. Martini, P. Rivera, A. Capobianco, M. Falco, E. Lanino, I. Pierri, R. Zambello, et al.
Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112)
Blood, March 1, 2005; 105(5): 2066 - 2073.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Poggi, C. Venturino, S. Catellani, M. Clavio, M. Miglino, M. Gobbi, A. Steinle, P. Ghia, S. Stella, F. Caligaris-Cappio, et al.
V{delta}1 T Lymphocytes from B-CLL Patients Recognize ULBP3 Expressed on Leukemic B Cells and Up-Regulated by Trans-Retinoic Acid
Cancer Res., December 15, 2004; 64(24): 9172 - 9179.
[Abstract] [Full Text] [PDF]


Home page
ASH ANNUAL MEETING ABSTRACTSHome page
H. R. Salih, P. Stieber, A. Peterfi, D. Nagel, L. Kanz, A. L. Steinle, and S. Holdenrieder
Determination of Soluble MICA in Serum as a Novel Marker for Tumor Stage and Metastasis.
Blood (ASH Annual Meeting Abstracts), November 16, 2004; 104(11): 1344 - 1344.
[Abstract]


Home page
JEMHome page
M. J. Smyth, J. Swann, J. M. Kelly, E. Cretney, W. M. Yokoyama, A. Diefenbach, T. J. Sayers, and Y. Hayakawa
NKG2D Recognition and Perforin Effector Function Mediate Effective Cytokine Immunotherapy of Cancer
J. Exp. Med., November 15, 2004; 200(10): 1325 - 1335.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
T. Igarashi, J. Wynberg, R. Srinivasan, B. Becknell, J. P. McCoy Jr, Y. Takahashi, D. A. Suffredini, W. M. Linehan, M. A. Caligiuri, and R. W. Childs
Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells
Blood, July 1, 2004; 104(1): 170 - 177.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. R. Verneris, M. Karami, J. Baker, A. Jayaswal, and R. S. Negrin
Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells
Blood, April 15, 2004; 103(8): 3065 - 3072.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
G. Ferlazzo and C. Munz
NK Cell Compartments and Their Activation by Dendritic Cells
J. Immunol., February 1, 2004; 172(3): 1333 - 1339.
[Full Text] [PDF]


Home page
J. Immunol.Home page
E. S. Doubrovina, M. M. Doubrovin, E. Vider, R. B. Sisson, R. J. O'Reilly, B. Dupont, and Y. M. Vyas
Evasion from NK Cell Immunity by MHC Class I Chain-Related Molecules Expressing Colon Adenocarcinoma
J. Immunol., December 15, 2003; 171(12): 6891 - 6899.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020